Alembic Pharmaceuticals has incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in the United Arab Emirates. The entity was established on September 1, 2026, by Alembic Global Holding SA, a wholly owned subsidiary of the listed company. This move aims to explore new business opportunities and promote the sale and distribution of the company's pharmaceutical products in the region.

The incorporation was disclosed to stock exchanges on October 19, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation regarding the formation of the wholly owned subsidiary was received by the parent company on the same date. The regulatory filing highlights that no specific governmental or regulatory approvals were required for this incorporation.

Subsidiary structure and ownership

Alvesta Pharmaceuticals FZCO operates as a step-down wholly owned subsidiary. It is held entirely by Alembic Global Holding SA, which itself is a wholly owned subsidiary of Alembic Pharmaceuticals. The ownership structure ensures complete control remains within the group hierarchy.

The capital structure involves a cash consideration subscription. Alembic Global Holding SA subscribed to 100 shares at a price of AED 1,000 each. This results in a total cost of subscription of AED 100,000. The subsidiary is classified under the pharmaceuticals industry.

Strategic intent

The primary objective of establishing Alvesta Pharmaceuticals FZCO is to facilitate the distribution of pharmaceutical products manufactured by the parent group. By setting up a dedicated entity in Dubai, the company seeks to strengthen its presence in the Middle East market. The filing specifies that the entity will focus on promoting, selling, and distributing these products.

This corporate action reflects a strategic expansion into international markets through a specialized distribution arm. The use of a Free Zone Company (FZCO) structure in the UAE typically offers operational benefits for trading entities. The minimal initial capital outlay of AED 100,000 indicates an initial setup phase for the new venture.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This regulatory clearance allows the company to market a generic equivalent to the reference listed drug product Ciprodex Otic Suspension in the United States.

The approved formulation is indicated for treating infections caused by susceptible isolates of designated microorganisms. Specifically, it addresses Acute Otitis Media (AOM) in pediatric patients aged six months and older with tympanostomy tubes, as well as Acute Otitis Externa (AOE) in pediatric, adult, and elderly patients aged six months and older.

Market Opportunity and Product Details

According to IQVIA data, the estimated market size for this specific suspension was $110 million for the twelve months ending June 2026. The product is therapeutically equivalent to the reference listed drug manufactured by Sandoz Inc., positioning Alembic to compete directly in this established therapeutic segment.

Regulatory Milestones

This approval adds to Alembic's growing portfolio of regulatory clearances in the US. The company now holds a cumulative total of 246 ANDA approvals from the USFDA. This portfolio comprises 226 final approvals and 20 tentative approvals, reflecting the company's sustained focus on complex generics and regulatory compliance.

What the Numbers Show

The receipt of this final approval underscores Alembic's strategic focus on high-value niche markets within the broader anti-infective category. With the target market valued at $110 million, this single product launch represents a tangible opportunity for revenue diversification. Furthermore, the achievement of 246 cumulative ANDA approvals highlights the company's operational maturity in navigating US regulatory pathways, providing a robust pipeline foundation for future launches.